Precision BioSciences (DTIL) News Today $4.88 +0.19 (+4.05%) As of 05/20/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock DTIL Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Uncovering Potential: Precision BioSciences's Earnings PreviewMay 16, 2025 | benzinga.comPrecision BioSciences Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 15, 2025 | businesswire.comPrecision BioSciences Accelerates Development of PBGENE-DMD Within its Wholly Owned Organic Pipeline and Highlights Pre-clinical Evidence at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingMay 14, 2025 | businesswire.comPrecision BioSciences Q1 2025 Earnings PreviewMay 14, 2025 | msn.comPrecision BioSciences (DTIL) Projected to Post Earnings on ThursdayMay 14, 2025 | americanbankingnews.comPrecision BioSciences, Inc. (NASDAQ:DTIL) Shares Sold by Alyeska Investment Group L.P.Alyeska Investment Group L.P. lessened its position in shares of Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) by 43.3% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 100,000 shares of the company's stock after selling 76,382 shMay 9, 2025 | marketbeat.comPrecision BioSciences to Report First Quarter 2025 Results on May 15, 2025May 8, 2025 | businesswire.comPrecision BioSciences (DTIL) to Release Earnings on MondayPrecision BioSciences (NASDAQ:DTIL) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-precision-biosciences-inc-stock/)May 7, 2025 | marketbeat.comPrecision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL)May 7, 2025 | businesswire.comPrecision BioSciences (DTIL) Receives a Buy from H.C. WainwrightMay 3, 2025 | theglobeandmail.comPrecision BioSciences Announces Multiple Presentations for In Vivo Gene Editing Programs at the American Society of Gene and Cell Therapy (ASGCT) Annual MeetingMay 1, 2025 | businesswire.comLynx1 Capital Management LP Makes New Investment in Precision BioSciences, Inc. (NASDAQ:DTIL)Lynx1 Capital Management LP purchased a new stake in Precision BioSciences, Inc. (NASDAQ:DTIL - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 766,051 shares of the company's stock, valued atApril 29, 2025 | marketbeat.comPrecision BioSciences, Inc. (NASDAQ:DTIL) Short Interest UpdatePrecision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) was the target of a significant growth in short interest in March. As of March 31st, there was short interest totalling 752,700 shares, a growth of 21.7% from the March 15th total of 618,300 shares. Based on an average trading volume of 468,200 shares, the short-interest ratio is currently 1.6 days. Approximately 21.8% of the shares of the stock are sold short.April 22, 2025 | marketbeat.comPrecision BioSciences stock rises following FDA Fast Track designationApril 15, 2025 | in.investing.comPrecision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis BApril 15, 2025 | businesswire.comPrecision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | businesswire.comInsider Buying: Precision BioSciences, Inc. (NASDAQ:DTIL) Director Buys 3,250 Shares of StockMarch 28, 2025 | insidertrades.comPrecision BioSciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Business UpdateMarch 26, 2025 | businesswire.comAssessing Precision BioSciences: Insights From 4 Financial AnalystsMarch 21, 2025 | nasdaq.comPrecision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025March 21, 2025 | businesswire.comPrecision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025March 20, 2025 | businesswire.comPrecision BioSciences presents preclinical data from PBGENE-DMD programMarch 19, 2025 | markets.businessinsider.comPrecision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceMarch 19, 2025 | businesswire.comFDA clears Precision BioSciences’ IND for PBGENE-HBV to treat HBVMarch 17, 2025 | markets.businessinsider.comPrecision BioSciences Announces Clearance of Investigational New Drug Application by the U.S. FDA for First-in-Class PBGENE-HBV Designed to Eliminate Root Cause of Chronic Hepatitis BMarch 17, 2025 | businesswire.comPrecision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-CelMarch 15, 2025 | seekingalpha.comPrecision BioSciences Announces Oral Presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceFebruary 24, 2025 | businesswire.comH.C. Wainwright Maintains Buy on Precision BioSciences StockFebruary 21, 2025 | uk.investing.comPrecision BioSciences Touts Encouraging Initial Safety And Antiviral Activity Of Hepatitis B Treatment CandidateFebruary 19, 2025 | benzinga.comPrecision BioSciences announces initial results from ELIMINATE-B trialFebruary 19, 2025 | markets.businessinsider.comPrecision Bio gains on early Phase 1 data for Hep B candidateFebruary 19, 2025 | msn.comPrecision BioSciences Announces Initial Safety and Antiviral Activity of PBGENE-HBV in the ELIMINATE-B Clinical TrialFebruary 19, 2025 | businesswire.comMaxCyte Enters Strategic License Agreement with TG Therapeutics for Cell-Based Therapy DevelopmentFebruary 12, 2025 | quiverquant.comPrecision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing ProgramsJanuary 29, 2025 | businesswire.comPrecision BioSciences, Inc. (NASDAQ:DTIL) Insider Sells $49,274.73 in StockJanuary 23, 2025 | insidertrades.comPrecision Biosciences' general counsel sells shares worth $42,765January 23, 2025 | msn.comPrecision Biosciences CEO sells $172,033 in stockJanuary 23, 2025 | msn.comPrecision BioSciences shares soar on promising gene editing trial resultsJanuary 10, 2025 | investing.comAdvancements in Precision BioSciences’ Gene Editing Platform Bolster Buy RatingJanuary 10, 2025 | markets.businessinsider.comPrecision Bio rises after Phase 1/2 data for gene editing therapy in OTC deficiencyJanuary 10, 2025 | msn.comBMO Capital Upgrades Precision BioSciences (DTIL)January 10, 2025 | msn.comPrecision BioSciences' Gene Editing Platform Has Differentiated Mechanism, And Is Potentially Competitive: AnalystJanuary 10, 2025 | benzinga.comGeno J. Germano Acquires 3,605 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) StockJanuary 3, 2025 | insidertrades.comJohn Alexander Kelly Acquires 2,113 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) StockJanuary 1, 2025 | insidertrades.comPrecision BioSciences, Inc. (NASDAQ:DTIL) Director Melinda Brown Purchases 3,016 SharesDecember 31, 2024 | insidertrades.comPrecision BioSciences Receives Approval in Hong Kong to Expand PBGENE-HBV Phase 1 ELIMINATE-B Trial for the Treatment of Chronic Hepatitis BDecember 18, 2024 | tmcnet.comShort Interest in Precision BioSciences, Inc. (NASDAQ:DTIL) Rises By 11.8%Precision BioSciences, Inc. (NASDAQ:DTIL - Get Free Report) was the target of a large growth in short interest in November. As of November 15th, there was short interest totalling 239,900 shares, a growth of 11.8% from the October 31st total of 214,600 shares. Approximately 6.5% of the company's stock are short sold. Based on an average daily volume of 75,900 shares, the short-interest ratio is presently 3.2 days.December 2, 2024 | marketbeat.comPrecision BioSciences (NASDAQ:DTIL) Trading Up 3.6% - Time to Buy?Precision BioSciences (NASDAQ:DTIL) Trading Up 3.6% - Time to Buy?November 29, 2024 | marketbeat.comPrecision BioSciences to Participate in Upcoming November Investor ConferencesNovember 21, 2024 | businesswire.comPrecision BioSciences to present preclinical PBGENE-HBV dataNovember 15, 2024 | markets.businessinsider.com Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Email Address DTIL Media Mentions By Week DTIL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. DTIL News Sentiment▼-0.480.65▲Average Medical News Sentiment DTIL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. DTIL Articles This Week▼62▲DTIL Articles Average Week Get Precision BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for DTIL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Kodiak Sciences News Tonix Pharmaceuticals News Cardiff Oncology News SOPHiA GENETICS News Voyager Therapeutics News Y-mAbs Therapeutics News CARGO Therapeutics News ADC Therapeutics News scPharmaceuticals News Nanobiotix News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:DTIL) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Precision BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Precision BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
